Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741115 | 0.98 | SHBG (0.38) | SHBGEPHX1 | |
| SCHEMBL6740280 | 0.98 | SHBG (0.38) | SHBGEPHX1 | |
| SCHEMBL6742975 | 0.98 | SHBG (0.38) | SHBGEPHX1 | |
| SCHEMBL6741301 | 0.95 | SHBG (0.30) | SHBG | |
| SCHEMBL9716381 | 0.91 | SHBG (0.32) | SHBG | |
| SCHEMBL19515178 | 0.91 | — | — | |
| SCHEMBL2840978 | 0.90 | SHBG (0.35) | SHBGEPHX1 | |
| SCHEMBL22283289 | 0.87 | — | — | |
| SCHEMBL5545142 | 0.86 | SHBG (0.37) | SHBGEPHX1 | |
| SCHEMBL20600327 | 0.84 | SHBG (0.41) | SHBGEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-04-06 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-24 | — | — | US | disclosed |
| EP-3935042-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | Conatus Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11136362-B2 | Peptide modulators of specific calcineurin protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | HISTOGEN, INC. | 2021-09-09 | — | — | US | disclosed |
| US-5968927-A | AZEPINO-INDOLE COMPOUNDS; TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, PREVENTION OF ISCHEMIC INJURY | IDUN PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0929311-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0920444-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5877197-A | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 1999-03-02 | — | — | US | disclosed |
| US-5869519-A | USE OF SUCH COMPOSITIONS IN THE TREATMENT OF PATIENTS SUFFERING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, FOR THE PREVENTION OF ISCHEMIC INJURY, AND FOR THE PRESERVATION OF ORGANS THAT ARE TO UNDERGO A TRANSPLANTATION | IDUN PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| CN-1207101-A | Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes | IDUM PHARMACEUTICALS INC (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0874850-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | Idun Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998011129-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011109-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | SHBG 2197/4885EPHX1 3556/4885 |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | SHBG 4186/4885EPHX1 900/4885 |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CASP1, CASP3, CASP6 | SHBG 3783/4885EPHX1 1194/4885 |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | SHBG 3182/4885EPHX1 3404/4885 |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | TTR, HSPBP1, HSPH1 | SHBG 2197/4885EPHX1 3556/4885 |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | SHBG 758/4885EPHX1 3399/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | SHBG 125/4885EPHX1 2049/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | SHBG 4186/4885EPHX1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.